



HB 1356

SUPPORT

OUR MISSION

To restore, protect, and advance the rights of women and girls through legal argument, policy advocacy, and public education

OUR VISION

Total liberation of women and girls from all forms of sex-based oppressions, including gender identity, male violence, commercial sexual exploitation, and reproductive coercion

Women's Liberation Front SUPPORTS HB 1356, a bill that extends the statute of limitations from when a person may file a claim for a violation of New Hampshire's prohibition on medical procedures intended to change a minor's "gender" from two years to ten years after a minor reaches the age of the majority.

Women's Liberation Front is a national nonpartisan 501(c)(3) nonprofit that works to restore, defend, and advance the rights of women and girls. Women and girls, especially those who are same-sex attracted, often take on a "gender identity" in the mistaken belief that they will be treated better if they were not female or that their same-sex attraction would be more appropriate if they transitioned to boys and men. As a result, the surge of youth going to gender clinics and seeking to change their sex are predominately female¹, which makes this issue especially relevant to the welfare of girls and women. Between 2017 to 2021, 18,000 minors in the US were taking puberty blockers and hormones and the numbers have been increasing ever since.^{2,3} In 2017, only 2% of teenagers identified as transgender⁴ but that percentage has grown to 3.3% with 724,000 youth now identifying as transgender.⁵ All this despite rigorous systematic reviews in the U.K.,⁶ Germany,⁷ and now the United States⁸ that reveal the evidence to support these treatments are incredibly poor. Because of this alarming trend, youths need extra protection through policy and law to safeguard them from procedures they may insist they need to conform to a "gender identity."

HB 1356 is correct to extend the statute of limitations for when someone may bring a claim against a violation of New Hampshire law as most who come to regret "gender transition" do not do so until 5-10 years into "treatment." Studies that claim transition regret are low are notorious for short follow-ups to confirm the "success" with authors who are at moderate to high risk for bias.^{9,10} The rate of transition regret may be dramatically higher than headlines would have us believe as a 2023 meta-analysis reviewed the available research and found rates of discontinuation of care, medical treatment, regret, and detransition were up to almost 30%,¹¹ noting that many patients do not inform their clinicians if they regret transition.¹²

Further, extending the statute of limitations for filing claims is important for victims to receive compensation for the harm that has been done to them. The list of health risks to women and girls from taking supraphysiologic doses of testosterone *alone*



OUR MISSION

To restore, protect, and advance the rights of women and girls through legal argument, policy advocacy, and public education

OUR VISION

Total liberation of women and girls from all forms of sex-based oppressions, including gender identity, male violence, commercial sexual exploitation, and reproductive coercion

include but are not limited to heart attack;^{13, 14} adverse lipid profile;¹⁵ erythrocytosis (dangerously high red blood cell count);¹⁶ blood clots;^{17, 18} high blood pressure;¹⁹ subclinical atherosclerosis (hardening of the arteries);²⁰ ovarian damage;²¹ uterine and endometrial pathology;²² infertility;^{21, 23} endometrial,²⁴ breast,²⁵ and liver cancers;²⁶ vaginal atrophy;^{27, 28} prostatic metaplasia;²⁹ pelvic pain³⁰ and pelvic floor dysfunction;³¹ neurological disorders such as idiopathic intracranial hypertension (IIH) which is characterized by high pressure around the brain which can result in headaches and vision loss;²⁵ psychiatric and behavioral disorders;²⁵ vaginal cuff dehiscence;³² and increased mortality.³³ If a woman or girl has her ovaries removed as a part of “gender affirming care,” she may also suffer loss of bone density.³⁴ With such a list of medical injuries that may arise from violating New Hampshire’s provisions, claimants deserve enough time to file a claim and hopefully receive fair compensation needed to help treat any ongoing health issues.

Women’s Liberation Front urges the state of New Hampshire to vote YES on HB 1356 to ensure that violations of New Hampshire policy are given a more appropriate time frame in which to file a claim.

Sincerely,

Women’s Liberation Front

¹ Block J. US transgender health guidelines leave age of treatment initiation open to clinical judgment. *BMJ*2022;378:o2303. <http://doi.org/10.1136/bmj.o2303> [pmid:36167353](https://pubmed.ncbi.nlm.nih.gov/36167353/)

² Respaut R, Terhune C. Number of transgender children seeking treatment surges in US. *Reuters* 2022 Oct 6. <https://www.reuters.com/investigates/special-report/usa-transyouth-data/>

³ Terhune C, Respaut R, Conlin M. As children line up at gender clinics, families confront many unknowns. *Reuters* 2022 Oct 6. <https://www.reuters.com/investigates/special-report/usa-transyouth-care/>

⁴ Johns MM, Lowry R, Andrzejewski J, et al. Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students—19 States and large urban school districts, 2017. *MMWR Morb Mortal Wkly Rep*2019;68:67-71. . <http://doi.org/10.15585/mmwr.mm6803a3> [pmid:30677012](https://pubmed.ncbi.nlm.nih.gov/30677012/)

⁵ Herman, JL, Flores, AR. How Many Adults and Youth Identify as Transgender in the United States? *UCLA Williams Institute*. August 2025. <https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/>



⁶ Cass, H. (2024). Independent review of gender identity services for children and young people:

Final report. <https://cass.independent-review.uk/home/publications/final-report>

OUR MISSION

To restore, protect, and advance the rights of women and girls through legal argument, policy advocacy, and public education

⁷ Zepf FD, König L, Kaiser A, Ligges C, Ligges M, Roessner V, Banaschewski T, Holtmann M. Beyond NICE: Aktualisierte systematische Übersicht zur Evidenzlage der Pubertätsblockade und Hormongabe bei Minderjährigen mit Geschlechtsdysphorie [Beyond NICE: Updated Systematic Review on the Current Evidence of Using Puberty Blocking Pharmacological Agents and Cross-Sex-Hormones in Minors with Gender Dysphoria]. *Z Kinder Jugendpsychiatr Psychother.* 2024;52(3):167-187. German.

<https://doi.org/10.1024/1422-4917/a000972>. Epub 2024 Feb 27. PMID: 38410090.

⁸ Department of Health and Human Services. Treatment for Pediatric Gender Dysphoria Review of Evidence and Best Practices. November 19, 2025.

<https://opa.hhs.gov/sites/default/files/2025-11/gender-dysphoria-report.pdf>

OUR VISION

Total liberation of women and girls from all forms of sex-based oppressions, including gender identity, male violence, commercial sexual exploitation, and reproductive coercion

⁹ Cohn, J. The Detransition Rate Is Unknown. *Archives of Sexual Behaviour* 52, 1937–1952 (2023). <https://doi.org/10.1007/s10508-023-02623-5>

¹⁰ Bustos VP, Bustos SS, Mascaro A, Del Corral G, Forte AJ, Ciudad P, Kim EA, Langstein HN, Manrique OJ. Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence. *Plastic and Reconstruction Surgery Global Open.* 2021 Mar 19;9(3):e3477. doi: 10.1097/GOX.0000000000003477. Erratum in: *Plast Reconstr Surg Glob Open.* 2022 Apr 28;10(4):e4340. <https://doi.org/10.1097/GOX.0000000000004340>. PMID: 33968550; PMCID: PMC8099405

¹¹ Expósito-Campos P, Salaberria K, Pérez-Fernández JI, Gómez-Gil E. Gender detransition: A critical review of the literature. *Actas Esp Psiquiatr.* 2023 May;51(3):98-118. Epub 2023 May 1. PMID: 37489555; PMCID: PMC10803846.

¹² Littman L. Individuals Treated for Gender Dysphoria with Medical and/or Surgical Transition Who Subsequently Detransitioned: A Survey of 100 Detransitioners. *Arch Sex Behav.* 2021 Nov;50(8):3353-3369. <http://doi.org/10.1007/s10508-021-02163-w>. Epub 2021 Oct 19. PMID: 34665380; PMCID: PMC8604821.

¹³ Alzahrani T, Nguyen T, Ryan A, et al. Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population. *Circulation: Cardiovascular Quality and Outcomes.* Vol. 12 No. 4. April 5, 2019.

<https://doi.org/10.1161/CIRCOUTCOMES.119.005597>

¹⁴ Nota NM, MD, Wiepjes CM, de Blok CJM. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy: Results From a Large Cohort Study. *Circulation.* Vol. 139. No. 11. February 18, 2019.

<https://doi.org/10.1161/CIRCULATIONAHA.118.038584>



OUR MISSION

To restore, protect, and advance the rights of women and girls through legal argument, policy advocacy, and public education

OUR VISION

Total liberation of women and girls from all forms of sex-based oppressions, including gender identity, male violence, commercial sexual exploitation, and reproductive coercion

¹⁵ Gosiker B, Moutchia J, Nguyen N, et al. Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis. *Journal of Clinical & Translational Endocrinology*. Volume 36, 100349. June 2024. <https://doi.org/10.1016/j.jcte.2024.100349>

¹⁶ Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. *The Journal of Clinical Endocrinology & Metabolism*, Volume 106, Issue 6. June 2021. pp 1710–1717, <https://doi.org/10.1210/clinem/dgab089>

¹⁷ van Zijverden LM, Wiepjes CM, van Diemen JJK, et al. Cardiovascular disease in transgender people: a systematic review and meta-analysis. *European Journal of Endocrinology*, Volume 190, Issue 2. February 2024, Pages S13–S24, <https://doi.org/10.1093/ejendo/lvad170>

¹⁸ Yelehe M, Klein M, El Aridi L, et al. Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database. *Fundamental & Clinical Pharmacology*. Vol. 36. Iss. 6. pp 1115-1124. June 2, 2022 <https://doi.org/10.1111/fcp.12806>

¹⁹ Banks K, Kyinn M, Leemaqz SY, et al. Blood Pressure Effects of Gender-Affirming Hormone Therapy in Transgender and Gender-Diverse Adults. *Hypertension*. Vol 77, No. 6. April 19, 2021. <https://doi.org/10.1161/HYPERTENSIONAHA.120.16839>

²⁰ Allgayer RMC, da Silva Borba G, Moraes RS, et al. The Effect of Gender-Affirming Hormone Therapy on the Risk of Subclinical Atherosclerosis in the Transgender Population: A Systematic Review. *Endocrine Practice*. Vol. 29, Iss. 6. June 2023. pp 498-507. <https://doi.org/10.1016/j.eprac.2022.12.017>

²¹ Bailie E, Maidarti M, Hawthorn R, et al. The ovaries of transgender men indicate effects of high dose testosterone on the primordial and early growing follicle pool. *Reproduction & Fertility*. Vol. 4, Iss. 2. April 26, 2023. <https://doi.org/10.1530/RAF-22-0102>

²² Grimstad FW, Fowler KG, New EP, et al. Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series. *American Journal of Obstetrics and Gynecology*. Vol. 220, Iss. 3. March 2019. pp. 257.e1-257.e7. <https://doi.org/10.1016/j.ajog.2018.12.021>

²³ De Roo C, Schneider F, Stolk THR, et al. Fertility in transgender and gender diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility. *Human Reproduction Update*. Vol. 31, Iss. 3, May-June 2025. pp 183–217. <https://doi.org/10.1093/humupd/dmae036>



²⁴ O'Connor RM, Scott ME, Bakkar R, et al. A case of endometrial intraepithelial neoplasia in a transgender man on testosterone therapy. *Gynecologic Oncology Reports*. Vol. 42. August 2022, 101031. <https://doi.org/10.1016/j.gore.2022.101031>

OUR MISSION

To restore, protect, and advance the rights of women and girls through legal argument, policy advocacy, and public education

²⁵ Gomez-Lumbreras A & Villa-Zapata L. Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database. *Annals of Pharmacology*. Vol. 58, Iss. 11. February 12, 2024. <https://doi.org/10.1177/10600280241231612>

²⁶ Lin AJ, Baranski T, Chaterjee D, et al. Androgen-receptor-positive hepatocellular carcinoma in a transgender teenager taking exogenous testosterone. *Clinical Picture*. Vol. 396, Iss. 10245. pp. 198. July 18, 2020. [http://doi.org/10.1016/S0140-6736\(20\)31538-5](http://doi.org/10.1016/S0140-6736(20)31538-5)

²⁷ Baldassarre M, Giannone AF, Foschini MP, et al. Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor- α and - β expression of young women. *International Journal of Impotence Research*. Vol. 25, Iss. 5. pp. 172. September-October 2013. Gale Academic OneFile, link.gale.com/apps/doc/A346526384/AONE?u=anon~7a854338&sid=googleScholar&xid=6ffc1a2b. Accessed 21 Jan. 2026.

OUR VISION

Total liberation of women and girls from all forms of sex-based oppressions, including gender identity, male violence, commercial sexual exploitation, and reproductive coercion

²⁸ Tordoff DM, Lunn MR, Chen B, et al. Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. *American Journal of Obstetrics & Gynecology*. Vol. 229, Iss. 6. pp. 669.e1-669.e17. December 2023. <http://doi.org/10.1016/j.ajog.2023.08.035>.

²⁹ Xu R, Diamond DA, Borer JG, et al. Prostatic metaplasia of the vagina in transmasculine individuals. *World Journal of Urology*. Published: 16 January 2022 Volume 40. pp. 849–855. March 2022. <https://doi.org/10.1007/s00345-021-03907-y>

³⁰ Zwickl S, Burchill L, Wong AFQ, et al. Pelvic Pain in Transgender People Using Testosterone Therapy. *Mary Ann Liebert*. Vol. 10, No. 3. April 3, 2023. <https://doi.org/10.1089/lgbt.2022.0187>

³¹ da Silva LMB, Freire SND, Moretti E, et al. Pelvic Floor Dysfunction in Transgender Men on Gender-affirming Hormone Therapy: A Descriptive Cross-sectional Study. *International Urogynecology Journal*. Vol. 35. pp. 1077-1084. April 25, 2024. <https://doi.org/10.1007/s00192-024-05779-3>

³² Wong JWH, Xu RH, Vega S, et al. Increased vaginal cuff dehiscence among gender diverse people on testosterone. *American Journal of Obstetrics and Gynecology*. Vol. 233, Iss. 4. pp. 30. e1-307.e8. March 27, 2025. <http://doi.org/10.1016/j.ajog.2025.03.027>

³³ de Blok CJM, Wiepjes CM, van Velzen DM, et al. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. *The Lancet Diabetes & Endocrinology*.



Vol. 9, Iss. 10. October 2021. pp. 663-670. [https://doi.org/10.1016/S2213-8587\(21\)00185-6](https://doi.org/10.1016/S2213-8587(21)00185-6)

³⁴ Sanna E, Lami A, Giacomelli G, et al. Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy. *Frontiers in Endocrinology*. Vol. 15. September 25, 2024. <https://doi.org/10.3389/fendo.2024.1416121>

OUR MISSION

To restore, protect,
and advance the
rights of women
and girls through
legal argument,
policy advocacy,
and public
education

OUR VISION

Total liberation of
women and girls
from all forms of
sex-based
oppressions,
including gender
identity, male
violence,
commercial
sexual
exploitation, and
reproductive
coercion